"Lipoprotein(a)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lipoprotein that resembles the LOW-DENSITY LIPOPROTEINS but with an extra protein moiety, APOPROTEIN (A) also known as APOLIPOPROTEIN (A), linked to APOLIPOPROTEIN B-100 on the LDL by one or two disulfide bonds. High plasma level of lipoprotein (a) is associated with increased risk of atherosclerotic cardiovascular disease.
| Descriptor ID |
D017270
|
| MeSH Number(s) |
D10.532.350 D12.776.521.400
|
| Concept/Terms |
Lipoprotein(a)- Lipoprotein(a)
- Lipoprotein Lp(a)
- Lipoprotein (a)
- Lipoprotein a
|
Below are MeSH descriptors whose meaning is more general than "Lipoprotein(a)".
Below are MeSH descriptors whose meaning is more specific than "Lipoprotein(a)".
This graph shows the total number of publications written about "Lipoprotein(a)" by people in this website by year, and whether "Lipoprotein(a)" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lipoprotein(a)" by people in Profiles.
-
Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, Gill EA, Jacobson TA, Michos ED, Safarova MS, Soffer DE, Taub PR, Wilkinson MJ, Wilson DP, Ballantyne CM. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024 May-Jun; 18(3):e308-e319.
-
Puri R, Ballantyne CM, Hoogeveen RC, Shao M, Barter P, Libby P, Chapman MJ, Erbel R, Arsenault BJ, Raichlen JS, Nissen SE, Nicholls SJ. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. Atherosclerosis. 2017 Aug; 263:137-144.
-
Cain WJ, Millar JS, Himebauch AS, Tietge UJ, Maugeais C, Usher D, Rader DJ. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res. 2005 Dec; 46(12):2681-91.
-
Ikewaki K, Cain W, Thomas F, Shamburek R, Zech LA, Usher D, Brewer HB, Rader DJ. Abnormal in vivo metabolism of apoB-containing lipoproteins in human apoE deficiency. J Lipid Res. 2004 Jul; 45(7):1302-11.
-
Starkman HS, Cable G, Hala V, Hecht H, Donnelly CM. Delineation of prevalence and risk factors for early coronary artery disease by electron beam computed tomography in young adults with type 1 diabetes. Diabetes Care. 2003 Feb; 26(2):433-6.
-
Frank PG, N'Guyen D, Franklin V, Neville T, Desforges M, Rassart E, Sparks DL, Marcel YL. Importance of central alpha-helices of human apolipoprotein A-I in the maturation of high-density lipoproteins. Biochemistry. 1998 Sep 29; 37(39):13902-9.
-
Frank PG, Bergeron J, Emmanuel F, Lavigne JP, Sparks DL, Denèfle P, Rassart E, Marcel YL. Deletion of central alpha-helices in human apolipoprotein A-I: effect on phospholipid association. Biochemistry. 1997 Feb 18; 36(7):1798-806.
-
Lafferty MA, Salamon AM, Usher DC. Immunochemistry of human Lp[a]: characterization of monoclonal antibodies that cross-react strongly with plasminogen. J Lipid Res. 1991 Feb; 32(2):277-92.